{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:52:55Z","timestamp":1771001575537,"version":"3.50.1"},"reference-count":93,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2004,11]]},"DOI":"10.1016\/j.clinthera.2004.11.006","type":"journal-article","created":{"date-parts":[[2005,1,6]],"date-time":"2005-01-06T12:15:12Z","timestamp":1105013712000},"page":"1701-1713","source":"Crossref","is-referenced-by-count":78,"title":["Role of the newer alpha, -adrenergic-receptor antagonistsin the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms"],"prefix":"10.1016","volume":"26","author":[{"given":"Franklin C.","family":"Lowe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2004.11.006_bib1","first-page":"7","article-title":"The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension","volume":"168","author":"Boyle","year":"1995","journal-title":"Scand J Urol Nephrol Suppl."},{"key":"10.1016\/j.clinthera.2004.11.006_bib2","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0022-5347(17)49698-4","article-title":"The development of human benign prostatic hyperplasia with age","volume":"132","author":"Berry","year":"1984","journal-title":"J Urol."},{"key":"10.1016\/j.clinthera.2004.11.006_bib3","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0140-6736(91)90543-X","article-title":"High prevalence of benign prostatic hypertrophy in the community","volume":"338","author":"Garraway","year":"1991","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2004.11.006_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1464-410X.1998.0810s1001.x","article-title":"Controversies in the management of lower urinary tract symptoms: An overview","volume":"81","author":"Coffey","year":"1998","journal-title":"Br J Urol"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2004.11.006_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0090-4295(00)00747-0","article-title":"The natural history of benign prostatic hyperplasia: What have we learned in the last decade?","volume":"56","author":"Kirby","year":"2000","journal-title":"Urology"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2004.11.006_bib6","first-page":"81","article-title":"Incidence of medically detected erectile dysfunction and related diseases before and after Viagra\u00ae (sildenafil citrate)","volume":"37","author":"Curkendall","year":"2000","journal-title":"Eur Urol."},{"issue":"Suppl 4","key":"10.1016\/j.clinthera.2004.11.006_bib7","first-page":"365","article-title":"Ejaculatory disorders are frequent and bothersome in ageing males with LUTS: A worldwide survey (MSAM-7)","volume":"169","author":"Rosen","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.clinthera.2004.11.006_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/01.HYP.12.1.1","article-title":"Sexual dysfunction in hypertensive men. A critical review of the literature","volume":"12","author":"Bansal","year":"1988","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2004.11.006_bib9","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1742-1241.2002.tb11312.x","article-title":"The effect of doxazosin on sexual function in patients with benign prostatic hyperplasia, hypertension, or both","volume":"56","author":"Flack","year":"2002","journal-title":"Int J Clin Pract"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2004.11.006_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0090-4295(01)01556-4","article-title":"Quality of life and alpha-blocker therapy: An important consideration for both the patient and the physician","volume":"59","author":"O'Leary","year":"2002","journal-title":"Urology"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2004.11.006_bib11","first-page":"3","article-title":"Results of an epidemiological survey in 3,500 French men aged 50 to 80 years with a special attention to urinary symptoms, quality of life and sexual function","volume":"37","author":"Richard","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.clinthera.2004.11.006_bib12","first-page":"249","article-title":"Assessing sexual function and urinary symptoms: Results of an epidemiological survey in 3,500 French men aged 50 to 80 years","volume":"163","author":"Richard","year":"2000","journal-title":"J Urol."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2004.11.006_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0090-4295(01)01554-0","article-title":"Goals for benign prostatic hyperplasia therapy","volume":"59","author":"Lowe","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2004.11.006_bib14","doi-asserted-by":"crossref","first-page":"815","DOI":"10.3109\/10641969909061011","article-title":"Drug treatment antihypertensive dings-the present role of beta blockers and alpha blockers","volume":"21","author":"Reid","year":"1999","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.clinthera.2004.11.006_bib15","first-page":"255","article-title":"The use of alpha adrenergic blockers in benign prostatic obstruction","volume":"48","author":"Caine","year":"1976","journal-title":"Br J Urol"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2004.11.006_bib16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0090-4295(01)01302-4","article-title":"Terazosin, doxazosin, and prazosin: Current clinical experience","volume":"58","author":"Akduman","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2004.11.006_bib17","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0090-4295(99)00041-2","article-title":"Impact of ding therapy on benign prostatic hyperplasia-specific quality of life","volume":"53","author":"Rhodes","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2004.11.006_bib18","first-page":"1378","article-title":"Evaluation and treatment of orthostatic hypotension","volume":"56","author":"Engstrom","year":"1997","journal-title":"Am Earn Physician."},{"key":"10.1016\/j.clinthera.2004.11.006_bib19","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1001\/jama.277.16.1299","article-title":"Patterns of orthostatic blood pressure change and their clinical correlates in a frail, elderly population","volume":"277","author":"Ooi","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2004.11.006_bib20","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1532-5415.2004.52203.x","article-title":"Effect of hip fracture on mortality in elderly women: The EPIDOS prospective study","volume":"52","author":"Empana","year":"2004","journal-title":"J Am Geriatr Soc."},{"key":"10.1016\/j.clinthera.2004.11.006_bib21","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0020-1383(00)00012-7","article-title":"Contralateral hip fractures-can predisposing factors be determined?","volume":"31","author":"Saxena","year":"2000","journal-title":"Injury"},{"key":"10.1016\/j.clinthera.2004.11.006_bib22","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1046\/j.1464-410X.1997.00205.x","article-title":"Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction(symptomatic benign prostatic hyperplasia)","volume":"80","author":"Buzelin","year":"1997","journal-title":"Br J Urol"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2004.11.006_bib23","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000052310","article-title":"History and nomenclature of alpha, adrenoceptors","volume":"36","author":"Langer","year":"1999","journal-title":"Eur Urol."},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2004.11.006_bib24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1464-410X.2000.00098.x","article-title":"Novel role for alpha, -adrenergic receptor subtypes in lower urinary tract symptoms","volume":"86","author":"Schwinn","year":"2000","journal-title":"BJU Int."},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2004.11.006_bib25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1464-410X.2000.00061.x","article-title":"Alpha,-adrenergic receptors in the lower urinary tract and vascular bed: Potential role for the alphald subtype in filling symp toms and effects ofageing on vascular expression","volume":"85","author":"Schwinn","year":"2000","journal-title":"BJU Int."},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2004.11.006_bib26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1464-410X.2001.00116.x","article-title":"The role of alpha,-adrenergic receptor subtypes in lower urinary tract symptoms","volume":"88","author":"Schwinn","year":"2001","journal-title":"BJU Int."},{"key":"10.1016\/j.clinthera.2004.11.006_bib27","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/S0022-5347(17)35954-2","article-title":"Characterization and localization of prostatic alpha 1 adrenoceptors using radioligand receptor binding on slide-mounted tissue section","volume":"150","author":"Kobayashi","year":"1993","journal-title":"J Urol."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2004.11.006_bib28","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1046\/j.1464-410X.1998.0810s1048.x","article-title":"Current status of research on prostateselective alpha 1-antagonists","volume":"81","author":"Kawabe","year":"1998","journal-title":"Br J Urol."},{"key":"10.1016\/j.clinthera.2004.11.006_bib29","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0022-5347(17)35544-1","article-title":"Identification, quantification, and localization of mRNA for three distinct alpha, adrenergic receptor subtypes in human prostate","volume":"150","author":"Price","year":"1993","journal-title":"J Urol."},{"key":"10.1016\/j.clinthera.2004.11.006_bib30","first-page":"267","article-title":"International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: Consensus update","volume":"47","author":"Hieble","year":"1995","journal-title":"Pharmacol Rev."},{"key":"10.1016\/j.clinthera.2004.11.006_bib31","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0022-5347(01)61986-4","article-title":"Localization and expression of the alpha1A-1 alpha1B and alpha1D- adrenoceptors in hyperplastic and non-hyperplastic human prostate","volume":"161","author":"Walden","year":"1999","journal-title":"J Urol."},{"key":"10.1016\/j.clinthera.2004.11.006_bib32","first-page":"684","article-title":"Categorization of adrenergic alpha 1 receptors in detmsor of patients with obstructive BPH. Initial study on experimental animal model","volume":"27","author":"Gonzalez Enguita","year":"2003","journal-title":"Actas Urol Esp."},{"key":"10.1016\/j.clinthera.2004.11.006_bib33","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0022-5347(05)65355-4","article-title":"Modulation of bladder alphai adrenergic receptor subtype expression by bladder outlet obstruction","volume":"167","author":"Hampel","year":"2002","journal-title":"J Urol."},{"key":"10.1016\/j.clinthera.2004.11.006_bib34","first-page":"147","article-title":"Cardiac alpha 1-adrenoceptors: An overview","volume":"45","author":"Terzic","year":"1993","journal-title":"Pharmacol Rev."},{"key":"10.1016\/j.clinthera.2004.11.006_bib35","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1161\/01.CIR.100.23.2336","article-title":"Subtype specific regulation of human vascular alpha, adrenergic receptors by vessel bed and age","volume":"100","author":"Rudner","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2004.11.006_bib36","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0091-3057(85)90535-0","article-title":"Distribution and function of peripheral alpha-adrenoceptors in the cardiovascular system","volume":"22","author":"Ruffolo","year":"1985","journal-title":"Pharmacol Biochem Behav."},{"key":"10.1016\/j.clinthera.2004.11.006_bib37","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s00345-001-0237-0","article-title":"Alpha- adrenoceptors and benign prostatic hyperplasia: Basic principles for treatment with alpha-adrenoceptor antagonists","volume":"19","author":"Andersson","year":"2002","journal-title":"World J Urol."},{"key":"10.1016\/j.clinthera.2004.11.006_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/01.HYP.19.1.1","article-title":"Epinephrine and the genesis of hypertension","volume":"19","author":"Floras","year":"1992","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2004.11.006_bib39","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1161\/01.HYP.33.2.640","article-title":"Heart rate and subsequent blood pressure in young adults: The CARDIA study","volume":"33","author":"Kim","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2004.11.006_bib40","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1001\/archinte.157.21.2413","article-title":"The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","volume":"157","year":"1997","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.clinthera.2004.11.006_bib41","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1046\/j.1464-410X.1997.00247.x","article-title":"Alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia: Past, present and future","volume":"80","author":"Kirby","year":"1997","journal-title":"Br J Urol."},{"key":"10.1016\/j.clinthera.2004.11.006_bib42","first-page":"265","article-title":"R0700004, a selective alpha 1Aadrenoceptor antagonist, does not improve lower urinary tract symptoms in men with benign prostatic hyperplasia","volume":"167","author":"Blue","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.clinthera.2004.11.006_bib43","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1464-410X.1989.tb05942.x","article-title":"Characterisation of human prostatic adrenoceptors using pharmacology receptor binding and localisation","volume":"63","author":"Chapple","year":"1989","journal-title":"Br J Urol."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2004.11.006_bib44","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1159\/000052318","article-title":"Clinical pharmacology of alpha1-adrenoceptor antagonists","volume":"36","author":"Kirby","year":"1999","journal-title":"Eur Urol."},{"key":"10.1016\/j.clinthera.2004.11.006_bib45","series-title":"Campbell's Urology","first-page":"1297","article-title":"Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia","author":"Roehrbom","year":"2002"},{"key":"10.1016\/j.clinthera.2004.11.006_bib46","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1006\/phrs.1996.0022","article-title":"The use of alpha-adrenoceptor antagonists in the pharmacological management of benign prostatic hypertrophy: An overview","volume":"33","author":"Hieble","year":"1996","journal-title":"Pharmacol Res."},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2004.11.006_bib47","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000052284","article-title":"Cardiovascular effects of alpha blockers for the treatment of symptomatic BPH","volume":"34","author":"De Mey","year":"1998","journal-title":"Eur Urol."},{"key":"10.1016\/j.clinthera.2004.11.006_bib48","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0090-4295(01)01448-0","article-title":"Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: Arandomized, placebo-controlled trial","volume":"58","author":"Roehrbom","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2004.11.006_bib49","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1159\/000052361","article-title":"Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia","volume":"37","author":"van Kerrebroeck","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.clinthera.2004.11.006_bib50","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0094-0143(21)00977-0","article-title":"Alpha-adrenergic blockers for the treatment of benign prostatic hyperplasia","volume":"17","author":"Caine","year":"1990","journal-title":"Urol Clin North Am."},{"key":"10.1016\/j.clinthera.2004.11.006_bib51","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0090-4295(96)00242-7","article-title":"Alpha-blockade: Monotherapy for hypertension and benign prostatic hyperplasia","volume":"48","author":"Kaplan","year":"1996","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2004.11.006_bib52","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2165\/00003495-199549020-00011","article-title":"Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia","volume":"49","author":"Fulton","year":"1995","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2004.11.006_bib53","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2165\/00003495-199957010-00002","article-title":"Alpha-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia","volume":"57","author":"Cooper","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2004.11.006_bib54","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1046\/j.1464-410x.2001.02032.x","article-title":"A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia","volume":"87","author":"Kirby","year":"2001","journal-title":"BJU Int."},{"key":"10.1016\/j.clinthera.2004.11.006_bib55","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0022-5347(17)36941-0","article-title":"A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia","volume":"148","author":"Lepor","year":"1992","journal-title":"J Urol."},{"key":"10.1016\/j.clinthera.2004.11.006_bib56","series-title":"Campbell's Urology","first-page":"1337","article-title":"Evaluation and nonsurgical management of benign prostatic hyperplasia","author":"Lepor","year":"2002"},{"key":"10.1016\/j.clinthera.2004.11.006_bib57","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0022-5347(05)67709-9","article-title":"The mechanism of adverse events associated with terazosin: An analysis of the Veterans Affairs Cooperative Study","volume":"163","author":"Lepor","year":"2000","journal-title":"J Urol."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2004.11.006_bib58","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1464-410X.1998.0810s1021.x","article-title":"Drug treatment of hypertension in the elderly: The role of alpha-adrenoceptor blockade","volume":"81","author":"Man in't Veld","year":"1998","journal-title":"Br J Urol."},{"key":"10.1016\/j.clinthera.2004.11.006_bib59","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0002-8703(96)90181-7","article-title":"Principal results of the Hypertension and Lipid Trial (HALT): A multicenter study of doxazosin in patients with hypertension","volume":"131","author":"Levy","year":"1996","journal-title":"Am Heart J."},{"key":"10.1016\/j.clinthera.2004.11.006_bib60","first-page":"65","article-title":"Current approaches to the management of BPH","volume":"6","author":"Kuritzky","year":"1998","journal-title":"Clin Geriatr."},{"key":"10.1016\/j.clinthera.2004.11.006_bib61","first-page":"18","article-title":"BPH management: Minimal to maximal","author":"Lepor","year":"1996","journal-title":"Patient Care"},{"key":"10.1016\/j.clinthera.2004.11.006_bib62","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0090-4295(99)00057-6","article-title":"Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications","volume":"54","author":"Lowe","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2004.11.006_bib63","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1524-6175.2001.00459.x","article-title":"Doxazosin added to single-drug therapy in hypertensive patients with benign prostatic hypertrophy","volume":"3","author":"Martell","year":"2001","journal-title":"J Ctin Hypertens (Greenwich)"},{"key":"10.1016\/j.clinthera.2004.11.006_bib64","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1001\/jama.283.15.1967","article-title":"Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The Antihypertensive and Lipid-Lowering Treatmentto Prevent Heart Attack Trial (ALLHAT)","volume":"283","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2004.11.006_bib65","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2004.11.006_bib66","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/(SICI)1097-0045(19970215)30:3<202::AID-PROS9>3.0.CO;2-N","article-title":"Prostatic alpha, adrenoceptors and uroselectivity","volume":"30","author":"Andersson","year":"1997","journal-title":"Prostate"},{"key":"10.1016\/j.clinthera.2004.11.006_bib67","first-page":"703","article-title":"The alpha 1adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned humanalpha Ic subtype","volume":"45","author":"Forray","year":"1994","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.clinthera.2004.11.006_bib68","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/j.1476-5381.1996.tb15480.x","article-title":"Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adreno ceptors: Binding, functional and in vivo studies","volume":"118","author":"Kenny","year":"1996","journal-title":"Br J Pharmacol."},{"key":"10.1016\/j.clinthera.2004.11.006_bib69","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.bjp.0700907","article-title":"The effects of tamsulosin, a high affinity antagonist at functional alpha IA- and alpha 1D-adrenoceptor subtypes","volume":"120","author":"Noble","year":"1997","journal-title":"Br J Pharmacol."},{"key":"10.1016\/j.clinthera.2004.11.006_bib70","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1464-410X.1997.00411.x","article-title":"Clinical comparison of selective and non selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: Studies on tamsulosin in a fixed dose and terazosin in increasing doses","volume":"80","author":"Lee","year":"1997","journal-title":"Br J Urol."},{"issue":"Suppl4","key":"10.1016\/j.clinthera.2004.11.006_bib71","first-page":"267","article-title":"Prospective, randomized trial to evaluate the side effect profile of tamsulosin vs. terazosin in 1983 men with benign prostatic hyperplasia","volume":"167","author":"Lowe","year":"2002","journal-title":"J Urol."},{"key":"10.1016\/j.clinthera.2004.11.006_bib72","first-page":"289","article-title":"Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: Studies on tamsulosin and terazosin in Chinese patients","volume":"29","author":"Na","year":"1998","journal-title":"J Med."},{"key":"10.1016\/j.clinthera.2004.11.006_bib73","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0090-4295(00)01042-6","article-title":"Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia","volume":"57","author":"Narayan","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2004.11.006_bib74","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0090-4295(98)00126-5","article-title":"Phase III multicenter placebo-controlled study of tamsulosin in benign prostatichyperplasia","volume":"51","author":"Lepor","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2004.11.006_bib75","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/S0022-5347(01)62386-3","article-title":"A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatichyperplasia","volume":"160","author":"Narayan","year":"1998","journal-title":"J Urol."},{"key":"10.1016\/j.clinthera.2004.11.006_bib76","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S0090-4295(01)01335-8","article-title":"Worldwide experience with alfuzosin and tamsulosin","volume":"58","author":"Michel","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2004.11.006_bib77","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2165\/00003495-200262010-00006","article-title":"Tamsulosin: An update of its role in the management of lower urinary tract symptoms","volume":"62","author":"Lyseng-Williamson","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2004.11.006_bib78","series-title":"Flomax capsules. Physicians' Desk Reference","first-page":"1006","year":"2004"},{"issue":"Suppl 6","key":"10.1016\/j.clinthera.2004.11.006_bib79","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000052595","article-title":"The efficacy and safety of a new once-a-day formulation of an alpha-blocker","volume":"39","author":"van Kerrebroeck","year":"2001","journal-title":"Eur Urol."},{"key":"10.1016\/j.clinthera.2004.11.006_bib80","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2165\/00003495-200262040-00009","article-title":"Alfuzosin: A review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia","volume":"62","author":"McKeage","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2004.11.006_bib81","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1046\/j.1464-410X.2003.04309.x","article-title":"Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: Apooled analysis of three double-blind, placebo-controlled studies","volume":"92","author":"Roehrbom","year":"2003","journal-title":"BJU Int."},{"key":"10.1016\/j.clinthera.2004.11.006_bib82","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/j.1476-5381.1993.tb13762.x","article-title":"Alfuzosin, a selective alpha 1-adrenoceptor antagonist in the lower urinary tract","volume":"109","author":"Lefevre-Borg","year":"1993","journal-title":"Br J Pharroacol."},{"key":"10.1016\/j.clinthera.2004.11.006_bib83","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0024-3205(98)00257-4","article-title":"Relationship between the effects of alfuzosin on rat urethral and blood pressures and its tissue concentrations","volume":"63","author":"Martin","year":"1998","journal-title":"Life Sci."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2004.11.006_bib84","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000052316","article-title":"Preclinical pharmacology of alpha1-adrenoceptor antagonists","volume":"36","author":"Martin","year":"1999","journal-title":"Eur Urol."},{"key":"10.1016\/j.clinthera.2004.11.006_bib85","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/00005392-199904010-00935","article-title":"Prostate selectivity of alpha 1 adrenoceptor blocken","volume":"161","author":"Eckert","year":"1999","journal-title":"J Urol."},{"key":"10.1016\/j.clinthera.2004.11.006_bib86","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0302-2838(03)00154-4","article-title":"Prostatic tissual distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administration","volume":"44","author":"Mottet","year":"2003","journal-title":"Eur Urol."},{"key":"10.1016\/j.clinthera.2004.11.006_bib87","first-page":"305","article-title":"Orally administered alfuzosin (ALF) has a high prostatic diffusion in benign prostatic hyperplasia tissue","volume":"163","author":"Motttet","year":"2000","journal-title":"J Urol."},{"key":"10.1016\/j.clinthera.2004.11.006_bib88","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1464-410X.1992.tb15665.x","article-title":"Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin","volume":"70","author":"Teillac","year":"1992","journal-title":"Br J Urol."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2004.11.006_bib89","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000052319","article-title":"Clinical experience in Europe with uroselective alpha, antagonists","volume":"36","author":"Debruyne","year":"1999","journal-title":"Eur Urol."},{"key":"10.1016\/j.clinthera.2004.11.006_bib90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000019919","article-title":"A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction","volume":"36","author":"Djavan","year":"1999","journal-title":"Eur Urol."},{"key":"10.1016\/j.clinthera.2004.11.006_bib91","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0302-2838(01)00016-1","article-title":"Longterm safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: Open-labelextension study","volume":"41","author":"van Kerrebroeck","year":"2002","journal-title":"Eur Urol."},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2004.11.006_bib92","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000052228","article-title":"The concept of uroselectivity","volume":"33","author":"Andersson","year":"1998","journal-title":"Eur Urol"},{"key":"10.1016\/j.clinthera.2004.11.006_bib93","doi-asserted-by":"crossref","first-page":"2387 2398.","DOI":"10.1056\/NEJMoa030656","article-title":"The long term effects of doxazosin, finasteride and combination therapy on the clinical progression of BPH","volume":"349","author":"McConnell","year":"2003","journal-title":"N Engl J Med."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:0149291804803370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:0149291804803370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T11:36:22Z","timestamp":1682940982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/0149291804803370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11]]},"references-count":93,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2004,11]]}},"alternative-id":["0149291804803370"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2004.11.006","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2004,11]]}}}